UK Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.49+0.03 (+0.46%)
At close: 4:00PM EDT
6.48 -0.01 (-0.15%)
After hours: 05:27PM EDT

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000

Full-time employees277

Key executives

NameTitlePayExercisedYear born
Dr. Gregory A. DemopulosCo-Founder, Chairman, CEO & Pres2.24MN/A1959
Mr. Michael A. JacobsenChief Accounting Officer, VP of Fin. & Treasurer543.75kN/A1958
Mr. Peter B. Cancelmo J.D.VP, Gen. Counsel & Corp. Sec.409.11kN/A1979
Dr. Pamela Pierce PalmerCo-FounderN/AN/A1963
Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of ScienceN/AN/A1957
Mr. Peter W. WilliamsVP of HRN/AN/A1968
Dr. J. Steven WhitakerVP of Clinical Devel. & Chief Medical OfficerN/AN/A1956
Dr. Catherine A. MelfiChief Regulatory Officer & VP of Regulatory Affairs and Quality SystemsN/AN/A1959
Ms. Nadia DacChief Commercial OfficerN/AN/A1970
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Corporate governance

Omeros Corporation’s ISS governance QualityScore as of 1 July 2021 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.